Brief: Innate Pharma: FDA Grants Fast Track Designation For SAR'579 / IPH6101 For Treatment Of Hematological Malignancies
08/06/2023 06:05
June 8 (Reuters) - Innate Pharma SA IPH.PA :
* SAR’579 / IPH6101 RECEIVES FDA FAST TRACK DESIGNATION IN
THE US
FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
Source text for Eikon: ID:nBwbxYhYka
Further company coverage: IPH.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Innate Pharma SA
See all newsFrance's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member
French and Benelux stocks-Factors to watch